Cargando…

Treatment of acute lymphoblastic leukemia with an rGel/BLyS fusion toxin

Acute lymphoblastic leukemia (ALL) is the most common malignancy affecting children and a major cause of mortality from hematopoietic malignancies in adults. A substantial number of patients become drug resistant during chemotherapy, necessitating the development of alternative modes of treatment. r...

Descripción completa

Detalles Bibliográficos
Autores principales:	Parameswaran, Reshmi, Yu, Min, Lyu, Mi-Ae, Lim, Min, Rosenblum, Michael G., Groffen, John, Heisterkamp, Nora
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2012
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3376225/ https://www.ncbi.nlm.nih.gov/pubmed/22373785 http://dx.doi.org/10.1038/leu.2012.54

Ejemplares similares

Combination of drug therapy in acute lymphoblastic leukemia with a CXCR4 antagonist
por: Parameswaran, Reshmi, et al.
Publicado: (2011)

B lymphocyte stimulator (BLyS) isoforms in systemic lupus erythematosus: disease activity correlates better with blood leukocyte BLyS mRNA levels than with plasma BLyS protein levels
por: Collins, Christopher E, et al.
Publicado: (2006)

Fusion Toxin BLyS-Gelonin Inhibits Growth of Malignant Human B Cell Lines In Vitro and In Vivo
por: Luster, Troy A., et al.
Publicado: (2012)

The current status of targeting BAFF/BLyS for autoimmune diseases
por: Ramanujam, Meera, et al.
Publicado: (2004)

Systemic lupus erythematosus and its ABCs (APRIL/BLyS complexes)
por: Stohl, William
Publicado: (2010)

Multi-Modality Therapeutics with Potent Anti-Tumor Effects: Photochemical Internalization Enhances Delivery of the Fusion Toxin scFvMEL/rGel
por: Selbo, Pål K., et al.
Publicado: (2009)

G-CSF–stimulated Neutrophils Are a Prominent Source of Functional BLyS
por: Scapini, Patrizia, et al.
Publicado: (2003)

Desensitization and treatment with APRIL/BLyS blockade in rodent kidney transplant model
por: Bath, Natalie M., et al.
Publicado: (2019)

Serum Soluble TACI, a BLyS Receptor, Is a Powerful Prognostic Marker of Outcome in Chronic Lymphocytic Leukemia
por: Kyrtsonis, Marie-Christine, et al.
Publicado: (2014)

BlyS is up-regulated by hypoxia and promotes migration of human breast cancer cells
por: Zhu, Jing, et al.
Publicado: (2012)

SLE - Systemic lupus erythematosus: a BLySful, yet BAFFling, disorder
por: Stohl, William
Publicado: (2003)

Antibodies Against Human BLyS and APRIL Attenuate EAE Development in Marmoset Monkeys
por: Jagessar, S. Anwar, et al.
Publicado: (2012)

Human BLyS Facilitates Engraftment of Human PBL Derived B Cells in Immunodeficient Mice
por: Schmidt, Madelyn R., et al.
Publicado: (2008)

Belimumab: Anti-BLyS Monoclonal Antibody; Benlysta™; BmAb; LymphoStat-B
Publicado: (2012)

Erratum to: Antibodies Against Human BLyS and APRIL Attenuate EAE Development in Marmoset Monkeys
por: Jagessar, S. Anwar, et al.
Publicado: (2012)

Elevated BLyS levels in patients with systemic lupus erythematosus: Associated factors and responses to belimumab
por: Roth, D A, et al.
Publicado: (2015)

Roles for BLyS family members in meeting the distinct homeostatic demands of innate and adaptive B cells
por: Sindhava, Vishal J., et al.
Publicado: (2013)

B Lymphocyte Stimulator (BLyS) Is Expressed in Human Adipocytes In Vivo and Is Related to Obesity but Not to Insulin Resistance
por: Müller, Nike, et al.
Publicado: (2014)

A pathogenic IFNα, BLyS and IL-17 axis in Systemic Lupus Erythematosus patients
por: López, Patricia, et al.
Publicado: (2016)

O-acetylated N-acetylneuraminic acid as a novel target for therapy in human pre-B acute lymphoblastic leukemia
por: Parameswaran, Reshmi, et al.
Publicado: (2013)

Enhanced immunogenicity of pneumococcal surface adhesin A (PsaA) in mice via fusion to recombinant human B lymphocyte stimulator (BLyS)
por: Gor, Dennis O, et al.
Publicado: (2011)

Autoantibody production significantly decreased with APRIL/BLyS blockade in murine chronic rejection kidney transplant model
por: Bath, Natalie M., et al.
Publicado: (2019)

Local BLyS production by T follicular cells mediates retention of high affinity B cells during affinity maturation
por: Goenka, Radhika, et al.
Publicado: (2014)

Cytotoxicity of VEGF(121)/rGel on vascular endothelial cells resulting in inhibition of angiogenesis is mediated via VEGFR-2
por: Mohamedali, Khalid A, et al.
Publicado: (2011)

BLyS/APRIL dual inhibition for IgG4-RD: a prospective single-arm clinical trial of telitacicept
por: Cai, Shaozhe, et al.
Publicado: (2023)

Photochemical activation of MH3-B1/rGel: a HER2-targeted treatment approach for ovarian cancer
por: Bull-Hansen, Bente, et al.
Publicado: (2015)

Treatment of human pre-B acute lymphoblastic leukemia with the Aurora kinase inhibitor PHA-739358 (Danusertib)
por: Fei, Fei, et al.
Publicado: (2012)

Association Between Changes in BLyS Levels and the Composition of B and T Cell Compartments in Patients With Refractory Systemic Lupus Erythematosus Treated With Belimumab
por: Regola, Francesca, et al.
Publicado: (2019)

APRIL/BLyS deficient rats prevent donor specific antibody (DSA) production and cell proliferation in rodent kidney transplant model
por: Bath, Natalie M., et al.
Publicado: (2022)

High Expression Levels of BLyS/BAFF by Blood Dendritic Cells and Granulocytes Are Associated with B-cell dysregulation in SIV-Infected Rhesus Macaques
por: Poudrier, Johanne, et al.
Publicado: (2015)

Development of resistance to dasatinib in Bcr/Abl-positive acute lymphoblastic leukemia
por: Fei, Fei, et al.
Publicado: (2010)

Post Hoc Analysis of the Phase II/III APRIL‐SLE Study: Association Between Response to Atacicept and Serum Biomarkers Including BLyS and APRIL
por: Gordon, Caroline, et al.
Publicado: (2016)

Blood B Lymphocyte Stimulator (BLyS)/BAFF levels may reflect natural immunity to HIV in highly exposed uninfected Beninese Commercial Sex Workers
por: Sabourin-Poirier, Catherine, et al.
Publicado: (2016)

Nilotinib treatment in mouse models of P190 Bcr/Abl lymphoblastic leukemia
por: Kaur, Pavinder, et al.
Publicado: (2007)

AMD3100 sensitizes acute lymphoblastic leukemia cells to chemotherapy in vivo
por: Yu, M, et al.
Publicado: (2011)

Increased B-cell activating factor (BAFF)/B-lymphocyte stimulator (BLyS) in primary antiphospholipid syndrome is associated with higher adjusted global antiphospholipid syndrome scores
por: van den Hoogen, Lucas L, et al.
Publicado: (2018)

Cytotoxicity of CD56-positive lymphocytes against autologous B-cell precursor acute lymphoblastic leukemia cells
por: Fei, Fei, et al.
Publicado: (2014)

Environment-mediated drug resistance in Bcr/Abl-positive acute lymphoblastic leukemia
por: Feldhahn, Niklas, et al.
Publicado: (2012)

Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosus
por: Furie, Richard, et al.
Publicado: (2008)

Natural Immunity to HIV is associated with Low BLyS/BAFF levels and low frequencies of innate marginal zone like CD1c(+) B-cells in the genital tract
por: Fourcade, Lyvia, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_ceu5br3n8ib834lf4es6nk28oc